GH1 and type 2 diabetes mellitus: Our results indicate that both agents are capable of increasing IGFBP-1 levels, highlighting the clinical relevance of incretin-based antidiabetic therapies in routine practice and suggesting a potential role of the GH/IGF-1 axis and IGFBP expression in the management of T2DM and in the prevention of its complications.